TW202130643A - 螺環o-醣蛋白-2-乙醯胺基-2-去氧-3-d-葡萄哌喃糖苷酶抑制劑 - Google Patents

螺環o-醣蛋白-2-乙醯胺基-2-去氧-3-d-葡萄哌喃糖苷酶抑制劑 Download PDF

Info

Publication number
TW202130643A
TW202130643A TW109137522A TW109137522A TW202130643A TW 202130643 A TW202130643 A TW 202130643A TW 109137522 A TW109137522 A TW 109137522A TW 109137522 A TW109137522 A TW 109137522A TW 202130643 A TW202130643 A TW 202130643A
Authority
TW
Taiwan
Prior art keywords
methyl
alkyl
compound
spiro
group
Prior art date
Application number
TW109137522A
Other languages
English (en)
Chinese (zh)
Inventor
納森 根南
凱文 Ｍ 庫其安
磊 張
芷莉 忻
傑佛瑞 凡索斯
萊恩 加恩踏西歐
Original Assignee
美商百健Ｍａ公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商百健Ｍａ公司 filed Critical 美商百健Ｍａ公司
Publication of TW202130643A publication Critical patent/TW202130643A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW109137522A 2019-10-29 2020-10-28 螺環o-醣蛋白-2-乙醯胺基-2-去氧-3-d-葡萄哌喃糖苷酶抑制劑 TW202130643A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962927268P 2019-10-29 2019-10-29
US62/927,268 2019-10-29

Publications (1)

Publication Number Publication Date
TW202130643A true TW202130643A (zh) 2021-08-16

Family

ID=73554493

Family Applications (1)

Application Number Title Priority Date Filing Date
TW109137522A TW202130643A (zh) 2019-10-29 2020-10-28 螺環o-醣蛋白-2-乙醯胺基-2-去氧-3-d-葡萄哌喃糖苷酶抑制劑

Country Status (8)

Country Link
US (1) US12565504B2 (enExample)
EP (1) EP4051682A1 (enExample)
JP (1) JP2023501949A (enExample)
CN (1) CN114929709B (enExample)
AR (1) AR120324A1 (enExample)
TW (1) TW202130643A (enExample)
UY (1) UY38934A (enExample)
WO (1) WO2021086966A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022095971A1 (zh) * 2020-11-06 2022-05-12 上海医药集团股份有限公司 一种螺杂环类化合物、其制备方法及应用
WO2025247394A1 (zh) * 2024-05-31 2025-12-04 纽欧申医药(上海)有限公司 含氮杂环化合物、其药物组合物及应用
CN119569746B (zh) * 2025-02-06 2025-05-13 纽欧申医药(上海)有限公司 含氮杂环化合物、其药物组合物及应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US5948807A (en) * 1997-09-03 1999-09-07 Regents Of The University Of Minnesota Spiroindanamines and Spiroindanimides
WO2007063385A2 (en) * 2005-12-01 2007-06-07 Pfizer Products Inc. Spirocyclic amine histamine-3 receptor antagonists
EP1847542A1 (en) * 2006-04-21 2007-10-24 Laboratorios del Dr. Esteve S.A. Spiro[benzopyran] or spiro[benzofuran] derivatives which inhibit the sigma receptor
ATE486877T1 (de) 2006-12-29 2010-11-15 Hoffmann La Roche Azaspiroderivate
WO2010141074A2 (en) * 2009-06-01 2010-12-09 President And Fellows Of Harvard College O-glcnac transferase inhibitors and uses thereof
AU2012298949B2 (en) * 2011-08-25 2016-09-22 Merck Patent Gmbh Pyrano [3, 2 - D] [1, 3] thiazole as glycosidase inhibitors
US9051269B2 (en) 2011-11-18 2015-06-09 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
EP2780014A4 (en) 2011-11-18 2015-07-01 Constellation Pharmaceuticals Inc MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF
WO2013078320A1 (en) 2011-11-21 2013-05-30 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
JP5989805B2 (ja) 2012-02-10 2016-09-07 コンステレーション・ファーマシューティカルズ・インコーポレイテッドＣｏｎｓｔｅｌｌａｔｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． メチル基変更酵素の調節物質、組成物及びその使用
MA38341B1 (fr) 2013-02-11 2018-11-30 Constellation Pharmaceuticals Inc Modulateurs d'enzymes de modification par méthylation, compositions et utilisations associées
PT2970272T (pt) * 2013-03-14 2019-06-05 Merck Patent Gmbh Inibidores de glicosidase
US9745305B2 (en) 2013-03-15 2017-08-29 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
US9969716B2 (en) 2013-08-15 2018-05-15 Constellation Pharmaceuticals, Inc. Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof
NZ727185A (en) * 2014-06-24 2018-04-27 Gilead Sciences Inc Phosphatidylinositol 3-kinase inhibitors
CN107912040B (zh) * 2014-10-10 2021-04-06 基因泰克公司 作为组蛋白脱甲基酶抑制剂的吡咯烷酰胺化合物
SMT202100699T1 (it) * 2016-06-16 2022-01-10 Denali Therapeutics Inc Pirimidin-2-ilammino-1h-pirazoli come inibitori di lrrk2 per l'uso nel trattamento di disturbi neurodegenerativi
US11186564B2 (en) * 2016-08-04 2021-11-30 Sunovion Pharmaceuticals Inc. Dual NAV1.2/5HT2a inhibitors for treating CNS disorders
AU2018216040A1 (en) 2017-02-06 2019-06-20 Janssen Pharmaceutica Nv OGA inhibitor compounds

Also Published As

Publication number Publication date
WO2021086966A1 (en) 2021-05-06
US12565504B2 (en) 2026-03-03
US20230060003A1 (en) 2023-02-23
CN114929709A (zh) 2022-08-19
EP4051682A1 (en) 2022-09-07
AR120324A1 (es) 2022-02-09
UY38934A (es) 2021-05-31
CN114929709B (zh) 2024-08-30
JP2023501949A (ja) 2023-01-20

Similar Documents

Publication Publication Date Title
US8946210B2 (en) Fused aminodihydrothiazine derivatives
US9139594B2 (en) Fused aminodihydropyrimidone derivatives
US7439251B2 (en) Methods and compositions for treatment of central and peripheral nervous system disorders and novel compounds useful therefor
US9079914B2 (en) Fused aminodihydro-oxazine derivatives
US20180179221A1 (en) Hpk1 inhibitors and methods of using same
US20100093999A1 (en) Novel fused aminodihydrothiazine derivative
KR20250035623A (ko) 척추소뇌성 운동실조증 유형 3을 치료하기 위한 화합물
CA3012560A1 (en) Glycosidase inhibitors
ES3057371T3 (en) Antagonists of the muscarinic acetylcholine receptor m4
US12565504B2 (en) Spirocyclic O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors
MX2014004254A (es) Derivados de carbamato / urea que contienen anillos de piperidina y piperazina como inhibidores del receptor h3.
AU2017208119B2 (en) 6,7,8,9-tetrahydro-5H-pyrido[2,3-d]azepine dopamine D3 ligands
CN111094293B (zh) 作为pde7抑制剂的取代的苯并噁唑和苯并呋喃化合物
CN116981673A (zh) 新颖噻二唑并嘧啶酮衍生物
CN109988170B (zh) 八氢吡咯并[3,4-c]吡咯衍生物及其用途
CN114555592B (zh) 作为m4激动剂的2-氮杂螺[3.4]辛烷衍生物
JP7663503B2 (ja) アゼチジニルｏ－糖タンパク質－２－アセトアミド－２－デオキシ－３－ｄ－グルコピラノシダーゼ阻害剤
CN109956945B (zh) 八氢吡咯并[3,4-c]吡咯衍生物及其用途
WO2023172475A2 (en) Non-aromatic cyclic-pyrimidine analogs as glucosylceramide synthase inhibitors
JP2023545196A (ja) 三複素環誘導体、その医薬組成物及び使用
HK1202865A1 (en) Tricyclic derivatives and their pharmaceutical uses and compositions
HK1174918B (en) Substituted hexahydrochromeno[3,4-b]pyrroles with affinity for the serotonin receptor (5-ht) family